Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited filings document foreign-issuer reporting for an ADR-listed battery materials and technology company. Its Form 6-K reports furnish ASX announcements, operating and financial results, material-event disclosures, material agreements, shareholder voting matters, and governance updates.
Company filings also record capital-structure activity such as applications for quotation of ordinary fully paid shares, notifications of unquoted equity securities, employee incentive performance rights, and director interest notices. These disclosures connect NOVONIX's public reporting with its ordinary shares, American depositary shares, incentive securities, and governance obligations as an Australian issuer with U.S. reporting.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.
Novonix Limited filed a Form 6-K providing several ASX Appendix 3Y notices that record changes in directors’ interests. The changes mainly reflect the issue of 195,938 share rights to multiple directors following shareholder approval at the AGM on 15 April 2026. For example, Ron Edmonds now holds 416,342 ordinary shares and 195,938 share rights, while Sharan Burrow holds 215,739 ordinary shares and 195,938 share rights. These changes are described as issues of share rights rather than trades during a closed period.
NOVONIX LIMITED has issued 1,371,566 new unquoted Share Rights as a separate security class. These rights were not issued for cash consideration and will rank equally in all respects from their issue date of 6 May 2026.
The Share Rights form a new, unquoted ASX security class and increase NOVONIX’s unquoted securities alongside existing performance rights, options, convertible notes and convertible debentures. The issue is being put to security holders for approval under ASX Listing Rule 7.1 at a meeting dated 15 April 2026.
NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights. These rights relate to 5,862,567 underlying ordinary shares, have an exercise price of $0.0000, become exercisable on December 31, 2028, and expire on December 31, 2029. The entry is recorded as a holding, with no buy or sell transaction reported.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.
After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.
Novonix Limited reported the issue of 5,862,567 unquoted NVXAD performance rights on May 5, 2026 under an employee incentive scheme. These rights were issued to key management personnel member Michael O'Kronley and are not intended to be quoted on ASX.
After this grant, Novonix has 861,442,940 NVX ordinary fully paid shares on issue, 35,021,775 NVXAD performance rights, 14,016,667 NVXAA options and 45,221,586 NVXAL convertible notes outstanding. The issue relied on exception 13 in ASX Listing Rule 7.2, so did not require separate security holder approval.
NOVONIX Limited has completed the sale of its NOVONIX Battery Technology Solutions Inc. (BTS) business in Nova Scotia, Canada to former CEO Dr. Chris Burns. The divestiture is framed as part of a strategy to focus on building a vertically integrated synthetic graphite supply chain in North America.
Key terms include a share equity sale of the BTS business, including all related assets and liabilities, for a transaction price of US$1.00. As part of the deal, NOVONIX receives a 15% equity stake in the cathode business that will operate as Dryve Battery Materials Inc., while the cash balance at BTS as of closing is targeted at US$2 million, subject to agreed adjustments.
Post-transaction, BTS is split into two independent companies: Avrion Battery Labs Inc., providing advanced battery testing and R&D services, and Dryve Battery Materials Inc., advancing a patented pCAM-free dry synthesis platform for lithium-ion cathode materials. NOVONIX will also provide certain transition services and grant the buyer a trademark license through 31 December 2026.
NOVONIX Limited reports key strategic and cash developments for the quarter ended 31 March 2026. The U.S. Government certified the company’s Riverside project for a previously allocated US$103 million Section 48C advanced manufacturing tax credit, expected when the first 11,000 tonnes per annum of capacity is placed in service before 7 April 2028, with credits that can be sold to a third party.
NOVONIX signed a binding term sheet to divest its Battery Technology Solutions business while retaining a 15% equity stake, and secured exclusive rights to evaluate buying adjacent Riverside land for US$26.5 million, a move the company says could enable more than US$200 million in potential capital savings if a 50,000 tpa build-out is consolidated on one site. The company also highlighted revised mass production timing for Panasonic Energy to the second half of 2027 and a changing U.S. trade environment for anode materials.
Financially, NOVONIX posted a quarterly operating cash outflow of US$14.4 million and invested US$6.8 million in property, plant, and equipment, mainly at Riverside. Cash and cash equivalents were US$57.1 million at quarter-end, equating to an estimated 4.0 quarters of funding based on recent cash usage. The company also received notice from Nasdaq that its ADRs no longer meet the US$1.00 minimum bid price requirement and is assessing options such as adjusting the ADR-to-ordinary share ratio.